Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer’s disease

Table 2 Biomarker characteristics

	Mean ± SD (Min - Max)	Effect size (Cohen’s d)	Minimal sample size (n)
FDG AD-ROIs/pons (BL)	1,28 ± 0.15 (1.01–1.51)
Δ (FDG AD-ROIs/pons) within 24 months	−0.05 ± 0.15 (− 0.37–0.32)	0.341	70
PiB global/cerebellar vermis (BL)	1.63 ± 0.22 (1.37–2.16)
Δ (PiB global/cerebellar vermis) within 24 months	0.12 ± 0.09 (− 0.05–0.25)	1.315	7
Cortical thickness global (BL) [mm]	2.31 ± 0.23 (1.87–2.80)
Δ Cortical thickness global within 24 months [mm]	−0.14 ± 0.15 (− 0.45–0.11)	0.914	12

SD Standard deviation, min Minimum, max Maximum, FDG ¹⁸F-fluordeoxyglucose, AD-ROIs Alzheimer’s disease signature regions of interest, BL At baseline, PiB ¹¹C-Pittsburgh compound B, global Region of interest equals entire grey matter, Δ Changes between baseline and follow up adjusted to a 24 months follow up period, negative values indicate decrease, positive values indicate increase compared to BL

ISSN: 1471-2377